1.科研項(xiàng)目 (1)山西省科技創(chuàng)新計(jì)劃創(chuàng)新平臺(tái)項(xiàng)目,2022P004,腫瘤免疫與靶向藥物研發(fā)實(shí)驗(yàn)室,10萬(wàn),2022.10-2025.10,在研,負(fù)責(zé)人 (2)中央引導(dǎo)地方科技發(fā)展基金,YDZJSX2022A057,40萬(wàn),2022.4-2025.4,主持,在研 2.學(xué)術(shù)論文 (1)CXCL8 induces M2 macrophages polarization and inhibits CD8+ T cell infiltration to generate an immunosuppressive microenvironment in colorectal cancer. FASEB J, 2023, published on line (通訊作者, 2區(qū)) (2) RNA demethylase ALKBH5 suppresses tumorigenesis via inhibitingproliferation and invasion and promoting CD8+ T cell infiltration in colorectal cancer. Translational Oncology, 2023, published on line (通訊作者, 3區(qū)) (3)miR-148a-3p silences the CANX/MHC-I pathway and impairs CD8+ T cell-mediated immune attack in colorectal cancer. FASEB J, 2021, 35(8):e21776 (通訊作者, 2區(qū)) 3.學(xué)術(shù)榮譽(yù):山西省優(yōu)秀青年學(xué)術(shù)帶頭人 4.科技獎(jiǎng)勵(lì):山西省科技進(jìn)步獎(jiǎng)二等獎(jiǎng),2023.11 5.發(fā)明專利:無(wú) 6.學(xué)術(shù)任職:山西省生物化學(xué)與分子生物學(xué)會(huì)常務(wù)理事 |